Do analysts prefer STEX or CCII?

Biosig Technologies presently has a consensus target price of $4.00, suggesting a potential upside of 459.44%. Given Biosig Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Biosig Technologies is more favorable than Cohen Circle Acquisition Corp. II. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biosig Technologies 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cohen Circle Acquisition Corp. II 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, STEX or CCII?

Cohen Circle Acquisition Corp. II has lower revenue, but higher earnings than Biosig Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biosig Technologies $40K 2,081.72 -$462.77M -$9.05 N/A Cohen Circle Acquisition Corp. II N/A N/A N/A N/A N/A

Is STEX or CCII more profitable?

Cohen Circle Acquisition Corp. II's return on equity of 0.00% beat Biosig Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Biosig Technologies N/A -462.48% -307.38% Cohen Circle Acquisition Corp. II N/A N/A N/A

Do analysts prefer STEX or KCHV?

Biosig Technologies currently has a consensus target price of $4.00, indicating a potential upside of 459.44%. Given Biosig Technologies' stronger consensus rating and higher possible upside, research analysts plainly believe Biosig Technologies is more favorable than Kochav Defense Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biosig Technologies 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Kochav Defense Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, STEX or KCHV?

Kochav Defense Acquisition has lower revenue, but higher earnings than Biosig Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biosig Technologies $40K 2,081.72 -$462.77M -$9.05 N/A Kochav Defense Acquisition N/A N/A N/A N/A N/A

Is STEX or KCHV more profitable?

Kochav Defense Acquisition's return on equity of 0.00% beat Biosig Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Biosig Technologies N/A -462.48% -307.38% Kochav Defense Acquisition N/A N/A N/A

Does the media refer more to STEX or TCPC?

In the previous week, Biosig Technologies and Biosig Technologies both had 3 articles in the media. Blackrock Tcp Capital's average media sentiment score of 0.73 beat Biosig Technologies' score of -0.03 indicating that Blackrock Tcp Capital is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biosig Technologies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Blackrock Tcp Capital 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, STEX or XRPN?

Armada Acquisition Corp. II has lower revenue, but higher earnings than Biosig Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biosig Technologies $40K 2,081.72 -$462.77M -$9.05 N/A Armada Acquisition Corp. II N/A N/A N/A N/A N/A

Is STEX or XRPN more profitable?

Armada Acquisition Corp. II's return on equity of 0.00% beat Biosig Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Biosig Technologies N/A -462.48% -307.38% Armada Acquisition Corp. II N/A N/A N/A

Does the media prefer STEX or XRPN?

In the previous week, Biosig Technologies had 2 more articles in the media than Armada Acquisition Corp. II. MarketBeat recorded 3 mentions for Biosig Technologies and 1 mentions for Armada Acquisition Corp. II. Armada Acquisition Corp. II's average media sentiment score of 0.15 beat Biosig Technologies' score of -0.03 indicating that Armada Acquisition Corp. II is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biosig Technologies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Armada Acquisition Corp. II 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate STEX or CEPV?

Biosig Technologies currently has a consensus target price of $4.00, suggesting a potential upside of 459.44%. Given Biosig Technologies' stronger consensus rating and higher possible upside, equities analysts plainly believe Biosig Technologies is more favorable than Cantor Equity Partners V. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biosig Technologies 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cantor Equity Partners V 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is STEX or CEPV more profitable?

Cantor Equity Partners V's return on equity of 4,995.14% beat Biosig Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Biosig Technologies N/A -462.48% -307.38% Cantor Equity Partners V N/A 4,995.14% 2.93%

Does the media favor STEX or CEPV?

In the previous week, Biosig Technologies had 1 more articles in the media than Cantor Equity Partners V. MarketBeat recorded 3 mentions for Biosig Technologies and 2 mentions for Cantor Equity Partners V. Cantor Equity Partners V's average media sentiment score of 0.34 beat Biosig Technologies' score of -0.03 indicating that Cantor Equity Partners V is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biosig Technologies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cantor Equity Partners V 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Biosig Technologies (STEX) Competitors

$0.72 +0.02 (+3.61%)

As of 09/4/2026 04:00 PM Eastern

Compare

STEX vs. CCII, KCHV, TCPC, XRPN, and CEPV

Should you buy Biosig Technologies stock or one of its competitors? Biosig Technologies's main competitors and comparable companies include Cohen Circle Acquisition Corp. II (CCII), Kochav Defense Acquisition (KCHV), Blackrock Tcp Capital (TCPC), Armada Acquisition Corp. II (XRPN), and Cantor Equity Partners V (CEPV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "asset management & custody banks" industry.

How does Biosig Technologies compare to Cohen Circle Acquisition Corp. II?

Biosig Technologies (NASDAQ:STEX) and Cohen Circle Acquisition Corp. II (NASDAQ:CCII) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

7.2% of Biosig Technologies shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Biosig Technologies had 3 more articles in the media than Cohen Circle Acquisition Corp. II. MarketBeat recorded 3 mentions for Biosig Technologies and 0 mentions for Cohen Circle Acquisition Corp. II. Cohen Circle Acquisition Corp. II's average media sentiment score of 0.00 beat Biosig Technologies' score of -0.03 indicating that Cohen Circle Acquisition Corp. II is being referred to more favorably in the news media.

Company	Overall Sentiment
Biosig Technologies	Neutral
Cohen Circle Acquisition Corp. II	Neutral

Biosig Technologies presently has a consensus target price of $4.00, suggesting a potential upside of 459.44%. Given Biosig Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Biosig Technologies is more favorable than Cohen Circle Acquisition Corp. II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cohen Circle Acquisition Corp. II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cohen Circle Acquisition Corp. II's return on equity of 0.00% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-462.48%	-307.38%
Cohen Circle Acquisition Corp. II	N/A	N/A	N/A

Cohen Circle Acquisition Corp. II has lower revenue, but higher earnings than Biosig Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	2,081.72	-$462.77M	-$9.05	N/A
Cohen Circle Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A

Summary

Biosig Technologies beats Cohen Circle Acquisition Corp. II on 7 of the 10 factors compared between the two stocks.

How does Biosig Technologies compare to Kochav Defense Acquisition?

Biosig Technologies (NASDAQ:STEX) and Kochav Defense Acquisition (NASDAQ:KCHV) are both small-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, Biosig Technologies had 3 more articles in the media than Kochav Defense Acquisition. MarketBeat recorded 3 mentions for Biosig Technologies and 0 mentions for Kochav Defense Acquisition. Kochav Defense Acquisition's average media sentiment score of 0.00 beat Biosig Technologies' score of -0.03 indicating that Kochav Defense Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Biosig Technologies	Neutral
Kochav Defense Acquisition	Neutral

7.2% of Biosig Technologies shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Biosig Technologies has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market. Comparatively, Kochav Defense Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

Biosig Technologies currently has a consensus target price of $4.00, indicating a potential upside of 459.44%. Given Biosig Technologies' stronger consensus rating and higher possible upside, research analysts plainly believe Biosig Technologies is more favorable than Kochav Defense Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kochav Defense Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Kochav Defense Acquisition's return on equity of 0.00% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-462.48%	-307.38%
Kochav Defense Acquisition	N/A	N/A	N/A

Kochav Defense Acquisition has lower revenue, but higher earnings than Biosig Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	2,081.72	-$462.77M	-$9.05	N/A
Kochav Defense Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Biosig Technologies beats Kochav Defense Acquisition on 8 of the 11 factors compared between the two stocks.

How does Biosig Technologies compare to Blackrock Tcp Capital?

Biosig Technologies (NASDAQ:STEX) and Blackrock Tcp Capital (NASDAQ:TCPC) are both small-cap finance companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Biosig Technologies currently has a consensus target price of $4.00, indicating a potential upside of 459.44%. Blackrock Tcp Capital has a consensus target price of $3.75, indicating a potential downside of 7.86%. Given Biosig Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Biosig Technologies is more favorable than Blackrock Tcp Capital.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Blackrock Tcp Capital	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Biosig Technologies has a net margin of 0.00% compared to Blackrock Tcp Capital's net margin of -61.27%. Blackrock Tcp Capital's return on equity of 13.85% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-462.48%	-307.38%
Blackrock Tcp Capital	-61.27%	13.85%	5.28%

7.2% of Biosig Technologies shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by insiders. Comparatively, 0.4% of Blackrock Tcp Capital shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Biosig Technologies and Biosig Technologies both had 3 articles in the media. Blackrock Tcp Capital's average media sentiment score of 0.73 beat Biosig Technologies' score of -0.03 indicating that Blackrock Tcp Capital is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Blackrock Tcp Capital	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Blackrock Tcp Capital has higher revenue and earnings than Biosig Technologies. Blackrock Tcp Capital is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	2,081.72	-$462.77M	-$9.05	N/A
Blackrock Tcp Capital	$201.79M	1.69	-$88.93M	-$1.28	N/A

Biosig Technologies has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market. Comparatively, Blackrock Tcp Capital has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

Summary

Biosig Technologies beats Blackrock Tcp Capital on 9 of the 15 factors compared between the two stocks.

How does Biosig Technologies compare to Armada Acquisition Corp. II?

Biosig Technologies (NASDAQ:STEX) and Armada Acquisition Corp. II (NASDAQ:XRPN) are both small-cap finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Armada Acquisition Corp. II has lower revenue, but higher earnings than Biosig Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	2,081.72	-$462.77M	-$9.05	N/A
Armada Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A

Biosig Technologies currently has a consensus target price of $4.00, suggesting a potential upside of 459.44%. Given Biosig Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Biosig Technologies is more favorable than Armada Acquisition Corp. II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Armada Acquisition Corp. II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 28.0% of Armada Acquisition Corp. II shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Biosig Technologies has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market. Comparatively, Armada Acquisition Corp. II has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

Armada Acquisition Corp. II's return on equity of 0.00% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-462.48%	-307.38%
Armada Acquisition Corp. II	N/A	N/A	N/A

In the previous week, Biosig Technologies had 2 more articles in the media than Armada Acquisition Corp. II. MarketBeat recorded 3 mentions for Biosig Technologies and 1 mentions for Armada Acquisition Corp. II. Armada Acquisition Corp. II's average media sentiment score of 0.15 beat Biosig Technologies' score of -0.03 indicating that Armada Acquisition Corp. II is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Armada Acquisition Corp. II	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Biosig Technologies beats Armada Acquisition Corp. II on 7 of the 11 factors compared between the two stocks.

How does Biosig Technologies compare to Cantor Equity Partners V?

Biosig Technologies (NASDAQ:STEX) and Cantor Equity Partners V (NASDAQ:CEPV) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

In the previous week, Biosig Technologies had 1 more articles in the media than Cantor Equity Partners V. MarketBeat recorded 3 mentions for Biosig Technologies and 2 mentions for Cantor Equity Partners V. Cantor Equity Partners V's average media sentiment score of 0.34 beat Biosig Technologies' score of -0.03 indicating that Cantor Equity Partners V is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cantor Equity Partners V	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.2% of Biosig Technologies shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cantor Equity Partners V has lower revenue, but higher earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than Cantor Equity Partners V, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	2,081.72	-$462.77M	-$9.05	N/A
Cantor Equity Partners V	N/A	N/A	$1.23M	$0.14	73.79

Biosig Technologies currently has a consensus target price of $4.00, suggesting a potential upside of 459.44%. Given Biosig Technologies' stronger consensus rating and higher possible upside, equities analysts plainly believe Biosig Technologies is more favorable than Cantor Equity Partners V.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cantor Equity Partners V	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cantor Equity Partners V's return on equity of 4,995.14% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-462.48%	-307.38%
Cantor Equity Partners V	N/A	4,995.14%	2.93%

Summary

Biosig Technologies beats Cantor Equity Partners V on 7 of the 13 factors compared between the two stocks.

Get Biosig Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STEX vs. The Competition

Export

Metric	Biosig Technologies	Capital Markets Industry	Finance Sector	NASDAQ Exchange
Market Cap	$80.37M	$5.74B	$14.30B	$12.91B
Dividend Yield	N/A	7.38%	5.88%	8.90%
P/E Ratio	-0.08	31.67	26.19	25.45
Price / Sales	2,081.72	1,219.64	517.37	79.31
Price / Cash	N/A	48.21	39.59	52.28
Price / Book	0.57	1.98	2.13	6.17
Net Income	-$462.77M	$419.47M	$1.32B	$350.08M
7 Day Performance	-7.36%	7.28%	3.84%	-0.14%
1 Month Performance	-1.41%	0.60%	1.61%	1.02%
1 Year Performance	N/A	7.46%	11.96%	14.51%

Biosig Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STEX Biosig Technologies	2.4587 of 5 stars	$0.72 +3.6%	$4.00 +459.4%	N/A	$80.37M	$40K	N/A	50
CCII Cohen Circle Acquisition Corp. II	N/A	$10.33 flat	N/A	N/A	$358.38M	N/A	N/A	2	Analyst Upgrade
KCHV Kochav Defense Acquisition	N/A	$10.44 flat	N/A	N/A	$357.65M	N/A	N/A	2	High Trading Volume
TCPC Blackrock Tcp Capital	1.1394 of 5 stars	$4.16 +1.0%	$3.75 -9.9%	-43.3%	$345.68M	$201.79M	N/A	24,900
XRPN Armada Acquisition Corp. II	1.1497 of 5 stars	$10.52 -0.3%	N/A	N/A	$333.27M	N/A	N/A	2	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STEX) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biosig Technologies (STEX) Competitors

STEX vs. CCII, KCHV, TCPC, XRPN, and CEPV

How does Biosig Technologies compare to Cohen Circle Acquisition Corp. II?

Summary

How does Biosig Technologies compare to Kochav Defense Acquisition?

Summary

How does Biosig Technologies compare to Blackrock Tcp Capital?

Summary

How does Biosig Technologies compare to Armada Acquisition Corp. II?

Summary

How does Biosig Technologies compare to Cantor Equity Partners V?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STEX vs. The Competition

Biosig Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biosig Technologies (STEX) Competitors

STEX vs. CCII, KCHV, TCPC, XRPN, and CEPV

How does Biosig Technologies compare to Cohen Circle Acquisition Corp. II?

Do institutionals & insiders hold more shares of STEX or CCII?

Does the media favor STEX or CCII?

Do analysts prefer STEX or CCII?

Is STEX or CCII more profitable?

Which has preferable valuation and earnings, STEX or CCII?

Summary

How does Biosig Technologies compare to Kochav Defense Acquisition?

Does the media refer more to STEX or KCHV?

Do insiders and institutionals have more ownership in STEX or KCHV?

Which has more risk & volatility, STEX or KCHV?

Do analysts prefer STEX or KCHV?

Is STEX or KCHV more profitable?

Which has stronger earnings and valuation, STEX or KCHV?

Summary

How does Biosig Technologies compare to Blackrock Tcp Capital?

Do analysts prefer STEX or TCPC?

Is STEX or TCPC more profitable?

Do institutionals and insiders have more ownership in STEX or TCPC?

Does the media refer more to STEX or TCPC?

Which has preferable earnings & valuation, STEX or TCPC?

Which has more volatility and risk, STEX or TCPC?

Summary

How does Biosig Technologies compare to Armada Acquisition Corp. II?

Which has better earnings and valuation, STEX or XRPN?

Do analysts rate STEX or XRPN?

Do insiders & institutionals have more ownership in STEX or XRPN?

Which has more volatility & risk, STEX or XRPN?

Is STEX or XRPN more profitable?

Does the media prefer STEX or XRPN?

Summary

How does Biosig Technologies compare to Cantor Equity Partners V?

Does the media favor STEX or CEPV?

Do institutionals & insiders hold more shares of STEX or CEPV?

Which has better valuation & earnings, STEX or CEPV?

Do analysts rate STEX or CEPV?

Is STEX or CEPV more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STEX vs. The Competition

Biosig Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools